The pharmacodynamics of sumatriptan in nitroglycerin-induced headache

Journal of Clinical Pharmacology

Volumn 39, Issue 1, 1999, Pages 17-29

  Fullerton, Terence ^a,b   Komorowski Swiatek, Denise ^a,b   Forrest, Alan ^a,b   Gengo, Fran M ^a,b  

^a MILLARD FILLMORE HOSPITAL   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE; SUMATRIPTAN SUCCINATE;

ADULT; ARTERY BLOOD FLOW; ARTERY CONSTRICTION; ARTERY DILATATION; ARTICLE; BLOOD FLOW VELOCITY; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE CEREBRAL ARTERY; MIGRAINE; NORMAL HUMAN; PHARMACODYNAMICS; SUBCUTANEOUS DRUG ADMINISTRATION; VOLUNTEER;

EID: 0032924253     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922007525     Document Type: Article

References (51)

1. Olesen J, Tfelt-Hansen P, Welch KMA (eds.): The Headaches. New York: Raven Press, 1993.
2. Lipton RB, Stewart WF: The epidemiology of migraine. Eur Neurol 1994;34(Suppl. 2):6-11.
3. Lissovoy G, Lazarus SS: The economic cost of migraine: present state of knowledge. Neurology 1994;44(Suppl. 4):S56-S62.
4. Osterhaus JT, Gutterman DL, Plachetka JR: Healthcare resources and lost labour costs of migraine headaches in the US. Pharmacoeconomics 1992;2:67-76.
5. Stang PE, Osterhaus JT: Impact of migraine in the United States: data from the National Health Interview Survey. Headache 1993;33:29-35.
6. Blau JN: Migraine: theories of pathogenesis. Lancet 1992;339:1202-1207.
7. Plosker GL, McTavish D: Sumatriptan: a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994;47:622-651.
8. Solomon GD: Therapeutic advances in migraine. J Clin Pharmacol 1993;33:200-209.
9. Zwetsloot CP, Caekebeke JFV, Jansen JC, Odink J, Ferrari MD: Blood flow velocity changes in migraine attacks: a transcranial Doppler study. Cephalalgia 1991;11:103-107.
10. Thie A, Fuhlendorf A, Spitzer K, Kunze K: Transcranial Doppler evaluation of common and classic migraine: Part II. Ultrasonic features during attacks. Headache 1990;30:209-215.
11. Friberg L, Olesen J, Iversen HK, Sperling B: Migraine pain associated with middle cerebral artery dilation: reversal by sumatriptan. Lancet 1991;338:13-17.
12. Caekebeke JFV, Ferrari MD, Zwetsloot CP, Jansen J, Saxena PR: Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks. Neurology 1992;42:1522-1526.
13. Diener HC, Peters C, Rudzio M, Noe A, Dichgans J, Haux R, et al: Ergotamine, flunarizine and sumatriptan do not change cerebral blood flow velocity in normal subjects and migraineurs. Jounal of Neurology 1990;238:245-250.
14. Totaro R, Matteis GD, Marini C, Prencipe M: Effect of sumatriptan on cerebral blood flow velocity measured by transcranial Doppler. Stroke 1993;24:516.
15. Baumel B: Migraine: a pharmacologic review with newer options and delivery modalities. Neurology 1994;44(Suppl. 3):S13-S17.
16. Product information, Cerenex Pharmaceuticals 1994.
17. Iversen HK, Olesen J, Tflet-Hansen P: Intravenous nitroglycerin as an experimental model of vascular headache: basic characteristics. Pain 1989;38:17-24.
18. Iversen HK, Holm S, Friberg L: Intracranial hemodynamics during intravenous nitroglycerin infusion. Cephalalgia 1989;9(Suppl. 10):84-85.
19. Dahl A, Russell D, Nyberg-Hansen R, Rootwelt K: Effect of nitroglycerin on cerebral circulation measured by transcranial Doppler and SPECT. Stroke 1989;20:1733-1736.
20. Zanette EM, Agnoli A, Cerbo R, Chiarotti F, Roberti C, Buzzi MG, Fieschi C: Transcranial Doppler (TCD) after nitroglycerin in migraine without aura. Headache 1991;31:596-598.
21. Iversen HK, Olesen J: Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan: a human model for development of migraine drugs. Cephalalgia 1996;16:412-418.
22. Schmetterer L, Wolzt M, Krejcy K, Graselli U, Findl O, Eichler HG, Singer EA: Cerebral and ocular hemodynamic effects of sumatriptan in the nitroglycerin headache model. Clin Pharmacol Ther 1996;60:199-205.
23. Iversen HK, Nielsen TH, Garre K, Tfelt-Hansen P, Olesen J: Dose-dependent headache response and dilatation of limb and extracranial arteries after three doses of 5-isosorbide-mononitrate. Eur J Clin Pharmacol 1992;42:31-35.
24. Schuster D, Komorowski D, Gengo FM: Determination of sumatriptan from serum with solid phase extraction by reverse phase high-performance liquid chromatography with fluorescence detection. J Chromatography B (accepted pending revisions).
25. Dayneka NL, Garg V, Jusko WJ: Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993;21:457-478.
26. Jusko WJ, Ko HC: Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 1994;56:406-419.
27. Steimer JL, Mallet A, Golmard JF, Biosvieux, JF: Alternative approaches to estimation of population pharmacokinetic parameters: comparisons with the nonlinear mixed effect model. Drug Metab Rev 1984;15:265-292.
28. Forrest A, Ballow CH, Nix DE, Birmingham MC, Schentag JJ: Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother 1993;37:1065-1072.
29. D'Argenio DZ, Schumitzky A: ADAPT II Users' Guide: Biomedical Simulations Resource. Los Angeles: University of Southern California, 1992.
30. Dalsgaard-Nielsen T: Migraine diagnostics with special reference to pharmacological tests. Int Arch Allergy 1955;7:312-322.
31. Peters GA: Migraine: diagnosis and treatment with emphasis on the migraine-tension headache, provocative tests and use of rectal suppositories. Proc Staff Meet Mayo Clin 1953;28:673-686.
32. Young WB, Silberstein SD: Transcranial Doppler: technique and application to headache. Headache 1991;32:136-142.
33. Thomsen LL, Iversen HK: Experimental and biological variation of three-dimensional transcranial Doppler measurements. J Appl Physiol 1993;75:2805-2810.
34. Caplan LR, Brass LM, DeWitt LD, Adams RJ, Gomez C, Otis S, et al: Transcranial Doppler ultrasound: Present status. Neurology 1990;40:696-700.
35. Abernathy M, Donnelly G, Kay G, Wieneke J, Morris S, Bergeson S, et al: Transcranial Doppler sonography in headache-free migraineurs. Headache 1994;34:198-203.
36. Thie A, Fuhlendorf A, Spitzer K, Kunze K: Transcranial Doppler evaluation of common and classic migraine: Part I. Ultrasonic features during the headache-free period. Headache 1990;30:201-208.
37. Totaro R, DeMatteis G, Marini C, Prencipe M: Cerebral blood flow in migraine with aura: a transcranial Doppler sonography study. Headache 1992;32:446-451.
38. Scott AK, Grimes S, Ng K, Critchley M, Breckenridge M, Thomson C, et al: Sumatriptan and cerebral perfusion in healthy volunteers. Br J Clin Pharmacol 1992;33:401-404.
39. Ferrari MD, Haan J, Blokland AK, Arndt JW, Minnee P, Zwinderman AH: Cerebral blood flow during migraine attacks without aura and effect of sumatriptan. Arch Neurol 1995;52:135-139.
40. Moskowitz MA: Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993;43(Suppl. 3):S16-S20.
41. Appenzeller O: Pathogenesis of migraine. Med Clin N Am 1991;75:763-789.
42. Wei EP, Moskowitz MA, Boccalini P, Kontos HA: Calcitonin gene-related peptide mediates nitroglycerin and sodium nitroprusside-induced vasodilatation in feline cerebral arterioles. Circulation Research 1992;70:1313-1319.
43. Shekar YC, Anand IS, Sarma R, Ferrari R, Wahi PL, Poole-Wilson PA: Effects of prolonged infusion of human alpha calcitonin gene-related peptide on hemodynamics, renal blood flow, and hormone levels in congestive heart failure. Am J Cardiol 1991;67:732-736.
44. Iversen HK, Olesen J: Nitroglycerin-induced headache is not dependent on histamine release: support for a direct nociceptive action of nitric oxide. Cephalalgia 1994;14:437-442.
45. Olesen J, Thomsen LL, Iversen H: Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol Sci 1994;15:149-153.
46. Thadani U, Sharma M, Thompson D, Prasad R, Goli V, Corn C: Intravenous nitroglycerin and tolerance in unstable angina (abstract). Circulation 1987;76(Suppl. 4):128.
47. Packer M, Hung Lee W, Kessler PD, Gottlieb SS, Medina N, Yushak M: Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987;317:799-804.
48. Zimrin D, Reichek N, Bogin KT, Aurigemma G, Douglas P, Berko B, Fung HL: Antianginal effects of intravenous nitroglycerin over 24 hours. Circulation 1988;77:1376-1384.
49. Elkayam U, Kulick D, McIntosh N, Roth A, Hsueh W, Rahimtoola SH: Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation 1987;76:577-558.
50. Abrams J: Pharmacology of nitroglycerin and long-acting nitrates. Am J Cardiol 1985;56:12A-18A.
51. Iversen HK, Nielsen TH, Tfelt-Hansen P, Olesen J: Lack of tolerance of headache and radial artery diameter during a 7 hour intravenous infusion of nitroglycerin. Eur J Clin Pharmacol 1983;44:47-50.